Edward Liu, MD
Infectious Disease · Neptune, NJNPI 1871587683
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,390 of the $54,690 with a category attached, or 70.2%. Gilead accounts for 91.8% of it on its own, with 43 other manufacturers making up the rest. Reporting peaked in 2019 at $19,167 and has fallen 90.4% since, to $1,847 in 2025. Among infectious disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 421 payments — averaging $129.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$50K
- Viiv Healthcare Company$696
- AbbVie$618
- Merck$532
- Insmed, Inc.$425
- Shionogi Inc$236
- plus $2K from 38 others
Across 149 payments — averaging $17,063 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.8M
- Regeneron$650K
- Pfizer$56K
- Merck$40K
- Cumberland Pharmaceuticals, Inc.$250
What the payments were for
- Consulting fees$1210%
- Speaking & faculty fees$38,39070%
- Travel & lodging$9,03217%
- Food & beverage$6,90813%
- Education$2390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 159 | $50,202 |
| Viiv Healthcare Company | 48 | $696 |
| AbbVie(2 entities) | 39 | $618 |
| Merck | 39 | $532 |
| Insmed, Inc. | 17 | $425 |
| Shionogi Inc | 7 | $236 |
| Johnson & Johnson | 15 | $224 |
| Theratechnologies Inc. | 12 | $180 |
| Astellas Pharma US Inc | 4 | $157 |
| Biomerieux Inc | 2 | $140 |
| Dynavax Technologies Corporation | 5 | $92 |
| Corcept Therapeutics | 5 | $88 |
| Melinta Therapeutics, LLC | 5 | $79 |
| Mannkind Corporation | 5 | $70 |
| Boehringer Ingelheim | 5 | $69 |
| Lilly USA, LLC | 4 | $65 |
| Amgen | 4 | $61 |
| Vyera Pharmaceuticals, LLC | 4 | $56 |
| Cumberland Pharmaceuticals, Inc. | 3 | $56 |
| GSK | 4 | $55 |
| Aimmune Therapeutics, Inc. | 3 | $45 |
| Pfizer | 3 | $41 |
| Cequr Corporation | 1 | $39 |
| Ferring Pharmaceuticals Inc. | 2 | $38 |
| AstraZeneca | 2 | $33 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Novo Nordisk | 2 | $29 |
| BD | 2 | $29 |
| Radius Health, Inc. | 2 | $29 |
| Regeneron | 1 | $24 |
| Novartis | 1 | $22 |
| Oxford Immunotec USA Inc | 1 | $22 |
| Bayer | 1 | $20 |
| Antares Pharma, Inc. | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Tolmar, Inc. | 1 | $17 |
| Fresenius Kabi USA, LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $14 |
| Sobi, Inc | 1 | $14 |
| Bristol Myers Squibb | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,690 in reported general payments places this provider in the 95th percentile of 334 infectious disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 281 | $1,130,284 |
| TivicayDolutegravir Sodium | 90 | $230,803 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 47 | $178,339 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 39 | $143,020 |
| DescovyEmtricitabine/Tenofov Alafenam | 39 | $97,961 |
| JulucaDolutegravir/Rilpivirine | 26 | $91,354 |
| XifaxanRifaximin | 21 | $77,191 |
| DovatoDolutegravir Sodium/Lamivudine | 24 | $73,669 |
| PifeltroDoravirine | 18 | $29,808 |
| Darunavir | 17 | $26,941 |
| Daptomycin | 11 | $23,209 |
| VemlidyTenofovir Alafenamide | 14 | $20,294 |
| EdurantRilpivirine Hcl | 11 | $15,389 |
| Vancomycin Hcl | 12 | $3,250 |
| Nevirapine ErNevirapine | 18 | $2,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Vemlidy | $50,202 | $1,248,539334 claims |
| Viiv Healthcare CompanyTivicay, Triumeq, Juluca, Dovato | $696 | $538,846179 claims |
| MerckPifeltro | $532 | $29,80818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 infectious disease providers in New Jersey.
Other infectious disease in Neptune
- Jose FuneNeptune$8K
- Keith GottesdienerRahway$2.1M
- Jihad SlimNewark$2.1M
- Maria SzabelaNewark$474K
- Ronald NahassHillsborough$213K
- Christopher LucastiSomers Point$112K
- Spartaco BellomoJersey City$111K
- Jack BoghossianBayonne$97K
- Adriana GrigoriuJersey City$89K
- Sukrut DwivediOakhurst$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.